搜索

application area

Xenotransplantation of islets of Langerhans

The pancreas is divided into exocrine part and endocrine part. The exocrine part accounts for 90% of the pancreas, which is mainly composed of acini and ductal system, and mainly secretes pancreatic juice;

Diabetes treatment

Diabetes is an endocrine disease caused by the disorder of nutrition and metabolism in human body. Its basic biochemical characteristics are continuous hyperglycemia, because insulin cannot play a normal physiological role in the target cells,

imgboxbg

About sinobiology

Hunan sinor Biotechnology Co., Ltd. is mainly engaged in the research and development and preparation of xenotransplantation products. The company has a high-level R & D team. In the field of xenotransplantation, he has carried out close cooperation research with the Institute of cell transplantation and gene therapy of Central South University (Central South University holds the state-owned equity part of the company).

 

At present, the company covers an area of 50 mu in Xiangjiang new area of Changsha National High tech Zone. In August 2012, the company established a production base of medical grade (DPF) donor pigs that meets the World Health Organization standards and has independent intellectual property rights. At the same time, it established a cGMP standard cell preparation center, which has initially covered the breeding, 

这是描述信息

Preclinical study

We have a cell preparation center and corresponding supporting equipment that meet the clinical requirements and cGMP standards, and use professional cell separation equipment to automatically separate and purify islet cells.

clinical research

We have a cell preparation center and corresponding supporting equipment that meet the clinical requirements and cGMP standards, and use professional cell separation equipment to automatically separate and purify islet cells.

Isolation and purification of islets of Langerhans

We have a cell preparation center and corresponding supporting equipment that meet the clinical requirements and cGMP standards, and use professional cell separation equipment to automatically separate and purify islet cells.

Donor pig breeding

We have a cell preparation center and corresponding supporting equipment that meet the clinical requirements and cGMP standards, and use professional cell separation equipment to automatically separate and purify islet cells.

NEWS

Wang Wei: a pathfinder of xenotransplantation

Wang Wei: a pathfinder of xenotransplantation

GuangmingDailyreporterlongJunyuAihua The36yearoldmaXiaojun(pseudonym)suffersfromtypeIdiabetes.Ifheeatsacorn,hisbloodsugarwillexceedthestandard.Heneedstotakealargedoseofinsulineverydaytoreducehisbloodsugar.AfterreceivingislettransplantationinXiangyathirdhospitalaofCentralSouthUniversity,MaXiaojun'sinsulininjectiondecreasedby80%,hislifereturnedtonormal,andhewasabletogoouttowork. "Hownicetoliveeasily!"MaXiaojunsaidthatthankstoProfessorWangWeiforallthis. WangWeiisaradiologistintheThirdXiangyaHospital.Hislong-termclinicalexperiencehasmadehimknowthatthepaincausedbydiabetesishardforordinarypeopletoimagine.TypeIdiabetesisthemostdifficult.Becauseoftheunstablebloodglucose,itwillleadtoavarietyoflife-threateningcomplications. Islettransplantationisoneofthemostlikelymethodstocurediabetes.However,theextremeshortageofhumandonorsmakesthispossibilitymoreandmoreremote. Canweusetheinterventionmethodtotreatdiabetesmellituswithisletcelltransplantationofanimalsotherthanhuman?Medicalscientistsallovertheworldgraduallyfocusonanimals,especiallypigs.Theresultsshowthatthereisonlyoneaminoacidinpiginsulinmoleculewhichisdifferentfromhumaninsulin,whichmakespigisletxenotransplantationthemostlikelycurefordiabetesintheworldandthehopeoflarge-scaleapplication. In1995,WangWeidecidedtoturntoxenotransplantation.Inthisyear,XiangyaThirdHospitalsupportedWangWei's100000yuanscientificresearchfund,launchedthepreliminaryresearchofislettransplantation,andestablishedtheislettransplantationlaboratory.Sincethen,WangWeibegantodevotehimselftotheresearchonthetreatmentofdiabetesbyislettransplantation,andtheresearchgrouphasalsobecomeoneoftheinternationalacademicteamsthatfirstcarriedoutrelevantresearch. (isletcells) After4yearsofresearch,WangWei'steamachievedabreakthroughinthetreatmentofdiabetesbyintrahepatictransplantationofporcinepancreaticislandcellsviahepaticartery.WiththeapprovaloftheformerMinistryofhealth,WangWei'steamcompleted22clinicaltrialsof"pighuman"islettransplantationindiabetespatientsfrom2000to2004,andachievedsignificanttherapeuticeffects.Theresultsshowedthattheinsulinuseof20patientswasreducedbymorethan30%,whichwas"effective";6of20patientswerereducedbymorethan50%,whichwas"significanteffect";oneofthemwas"temporarilycured"foroneweek. In2005,WangWei'steamalsoachievedthreemajorbreakthroughs:creatingasafermethodofliverarterytransplantationinsteadofportalveinimplantation,findingobviousdifferencesinsideeffectsamongdifferenthumanspeciesinantirejectiontreatment,andexploringdifferentantirejectiontreatmentmethodsinxenotransplantationandhomotransplantationofisletsofLangerhans.InMayofthesameyear,WangWei'sClinicalResearchReportonthetreatmentoftypeIdiabetesmellituswithporcineisletcelltransplantationwashighlypraisedatthe9thAnnualMeetingoftheInternationalAssociationofpancreasislettransplantationheldinGeneva,Switzerland.InAugust,ProfessorCarlgross,whowasthechairmanoftheNobelPrizeforphysiologicalmedicine,praisedWangWeiforhis"pioneeringwork". Therearetoomanyhardshipsandsweatbehindthehalo. Inordertofindthemostsuitablepigprovenance,WangWeiwentuptotheQinghaiTibetPlateauinthenorthanddowntoHainanIslandinthesouth,andscreeneddozensofpigprovenancesinremotevillagesinmorethantenprovinces.Inrecentyears,WangWeihastraveledtensofthousandsofmiles,collectedandstudied11uniquepurepigbreedsinChina,selectedthemostsuitablepigsourcefortransplantation,andestablishedtwoinitialpigsourcebasesinHunanProvince. (xenograftdonorpig) Attheendof2012,WangWei'steamestablishedtheworld'ssecondDPFdonorpigbreedingcenterinChangsha.In2013,theclinicalstudyofxenotransplantationofisletsofLangerhanswasapprovedbythecompetentdepartmentofthegovernment.In2016,itpassedthemid-termreviewoftherapeuticeffectbyexpertsorganizedbythehealthandFamilyPlanningCommissionofHunanProvince.In2017,itpassedthefinalreviewoftherapeuticeffectbyexpertsorganizedbythehealthandFamilyPlanningCommissionofHunanProvince.Thismeansthatxenotransplantationcanfinallyentertheclinicalpractice,benefitingtensofmillionsofordinarypatients. Withtheproblemofscientificresearchbeingsolvedonebyone,abiggerproblemappearedinfrontofWangWei,thatis,thenorm.TheconscienceandsenseofresponsibilityofscientistsalwaysremindWangWeithatxenotransplantationisamajorsubjectandhasgreatbusinessopportunities.Withoutaunifiedandstrictinternationalstandard,itisverydangerousandcontrarytotheoriginalintentionofscientificresearch. Atthebeginningof2006,WangWeistartedthetransformationandinnovationfromthepuretechnicalandtheoreticalresearchofxenotransplantationtotherelatedresearchofestablishinginternationalstandardizedpreclinicalresearchofxenotransplantation,andtooktheleadintheinvestigationofformulatingxenotransplantationnormsinChina.InNovember2008,the"InternationalSymposiumonclinicalresearchnormsofglobalxenotransplantation"washeldinXiangyaThirdHospital,whichformulatedtheChangshadeclaration,aglobalxenotransplantationprogrammaticdocument.Forthefirsttime,theinternationalmedicalclinicalnormswerebrandedwith"Chinesestamp". (Changshadeclaration) InDecember2018,theThirdWorldHealthOrganizationSymposium